These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 19365143

  • 1. Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction.
    Briana DD, Boutsikou M, Baka S, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A.
    Neonatology; 2009; 96(2):132-6. PubMed ID: 19365143
    [Abstract] [Full Text] [Related]

  • 2. Perinatal bone turnover in term pregnancies: the influence of intrauterine growth restriction.
    Briana DD, Gourgiotis D, Boutsikou M, Baka S, Hassiakos D, Vraila VM, Creatsas G, Malamitsi-Puchner A.
    Bone; 2008 Feb; 42(2):307-13. PubMed ID: 18024242
    [Abstract] [Full Text] [Related]

  • 3. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth.
    Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, Hassiakos D, Malamitsi-Puchner A.
    J Matern Fetal Neonatal Med; 2008 Nov; 21(11):826-30. PubMed ID: 19031279
    [Abstract] [Full Text] [Related]

  • 4. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates.
    Boutsikou T, Malamitsi-Puchner A, Economou E, Boutsikou M, Puchner KP, Hassiakos D.
    Early Hum Dev; 2006 Apr; 82(4):235-9. PubMed ID: 16337100
    [Abstract] [Full Text] [Related]

  • 5. Associations of novel adipocytokines with bone biomarkers in intra uterine growth-restricted fetuses/neonates at term.
    Briana DD, Boutsikou M, Boutsikou T, Malamitsi-Puchner A.
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):984-8. PubMed ID: 24106768
    [Abstract] [Full Text] [Related]

  • 6. Soluble fas antigen and soluble fas ligand in intrauterine growth restriction.
    Briana DD, Baka S, Boutsikou M, Liosi S, Vraila VM, Gourgiotis D, Hassiakos D, Malamitsi-Puchner A.
    Neonatology; 2010 Jul; 97(1):31-5. PubMed ID: 19590243
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O.
    Nephron Clin Pract; 2007 Jul; 105(4):c153-8. PubMed ID: 17259742
    [Abstract] [Full Text] [Related]

  • 8. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Jul; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 9. Omentin-1 and vaspin are present in the fetus and neonate, and perinatal concentrations are similar in normal and growth-restricted pregnancies.
    Briana DD, Boutsikou M, Baka S, Gourgiotis D, Marmarinos A, Liosi S, Hassiakos D, Malamitsi-Puchner A.
    Metabolism; 2011 Apr; 60(4):486-90. PubMed ID: 20488498
    [Abstract] [Full Text] [Related]

  • 10. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Apr; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 11. Serum cystatin C in pregnancies with normal and restricted fetal growth.
    Malamitsi-Puchner A, Briana DD, Kontara L, Boutsikou M, Baka S, Hassiakos D, Marmarinos A, Gourgiotis D.
    Reprod Sci; 2007 Jan; 14(1):37-42. PubMed ID: 17636214
    [Abstract] [Full Text] [Related]

  • 12. N-terminal parathyroid hormone-related protein levels in human intrauterine growth restricted pregnancies.
    Briana DD, Boutsikou M, Baka S, Hassiakos D, Gourgiotis D, Marmarinos A, Iacovidou N, Malamitsi-Puchner A.
    Acta Obstet Gynecol Scand; 2007 Jan; 86(8):945-9. PubMed ID: 17653879
    [Abstract] [Full Text] [Related]

  • 13. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S.
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [Abstract] [Full Text] [Related]

  • 14. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.
    Arch Immunol Ther Exp (Warsz); 2005 Aug; 53(5):454-64. PubMed ID: 16314829
    [Abstract] [Full Text] [Related]

  • 15. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
    Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F.
    Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
    [Abstract] [Full Text] [Related]

  • 16. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007 May; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 17. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [Abstract] [Full Text] [Related]

  • 18. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L, Dolzani P, Silvestri T, Caraceni P, Facchini A, Ravaglia G, Salvarani C, Melicòni R, Mariani E.
    Biogerontology; 2004 Dec; 5(2):119-27. PubMed ID: 15105586
    [Abstract] [Full Text] [Related]

  • 19. Enhanced circulating retinol and non-esterified fatty acids in pregnancies complicated with intrauterine growth restriction.
    Ortega-Senovilla H, Alvino G, Taricco E, Cetin I, Herrera E.
    Clin Sci (Lond); 2009 Nov 23; 118(5):351-8. PubMed ID: 19656084
    [Abstract] [Full Text] [Related]

  • 20. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA, Mohamed NA, El-Metwally TH, Kamal MM.
    J Pediatr Hematol Oncol; 2010 May 23; 32(4):267-73. PubMed ID: 20445416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.